OTCMKTS:AITB - AIT Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AIT Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.20 -0.25 (-3.88 %) (As of 01/28/2020 04:00 PM ET) Add Compare Today's Range$6.06Now: $6.20▼$6.4650-Day Range$3.57MA: $5.22▼$6.8552-Week Range$3.11Now: $6.20▼$6.25Volume184,397 shsAverage Volume19,435 shsMarket Capitalization$65.60 millionP/E RatioN/ADividend YieldN/ABeta-0.31 ProfileAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AIT Therapeutics, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Garden City, New York. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:AITB Previous Symbol CUSIPN/A CIKN/A Webhttp://www.ait-therapeutics.com/ Phone972-8684-3313Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($3.01) Net Income$-18,040,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-100.76%Miscellaneous Employees10 Outstanding Shares10,581,000Market Cap$65.60 million Next Earnings DateN/A OptionableNot Optionable Receive AITB News and Ratings via Email Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter. OTC:AITB Rates by TradingView AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions What is AIT Therapeutics' stock symbol? AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB." Has AIT Therapeutics been receiving favorable news coverage? Media stories about AITB stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AIT Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the next few days. View News Stories for AIT Therapeutics. Who are some of AIT Therapeutics' key competitors? Some companies that are related to AIT Therapeutics include RenovaCare (RCAR), Vapotherm (VAPO), Repro-Med Systems (REPR), Repro Med Systems (KRMD), Restoration Robotics (HAIR), Soliton (SOLY), TELA Bio (TELA), iCAD (ICAD), Venus Concept (VERO), Cytosorbents (CTSO), BRAINSWAY LTD/S (BWAY), Liquidia Technologies (LQDA), Spectral Medical (EDTXF), BeyondAirInc . (XAIR) and Neuronetics (STIM). What other stocks do shareholders of AIT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIT Therapeutics investors own include Allena Pharmaceuticals (ALNA), Harvard Bioscience (HBIO), Obseva (OBSV), Athersys (ATHX), Deciphera Pharmaceuticals (DCPH), FormFactor (FORM), Professional Diversity Network (IPDN), MediciNova (MNOV), Pieris Pharmaceuticals (PIRS) and Protagonist Therapeutics (PTGX). Who are AIT Therapeutics' key executives? AIT Therapeutics' management team includes the folowing people: Mr. Steven Adam Lisi, CEO & Chairman (Age 48)Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 45)Mr. Douglas J. Beck, Chief Financial Officer (Age 58)Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory BoardDr. Giora Davidai M.D., Chief Medical Officer How do I buy shares of AIT Therapeutics? Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is AIT Therapeutics' stock price today? One share of AITB stock can currently be purchased for approximately $6.20. How big of a company is AIT Therapeutics? AIT Therapeutics has a market capitalization of $65.60 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 10 workers across the globe.View Additional Information About AIT Therapeutics. What is AIT Therapeutics' official website? The official website for AIT Therapeutics is http://www.ait-therapeutics.com/. How can I contact AIT Therapeutics? AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313. MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 81 (Vote Outperform)Underperform Votes: 97 (Vote Underperform)Total Votes: 178MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: What is the Consumer Price Index (CPI)?
